CN1852713B - 孟鲁司特钠的多晶型 - Google Patents

孟鲁司特钠的多晶型 Download PDF

Info

Publication number
CN1852713B
CN1852713B CN2004800163215A CN200480016321A CN1852713B CN 1852713 B CN1852713 B CN 1852713B CN 2004800163215 A CN2004800163215 A CN 2004800163215A CN 200480016321 A CN200480016321 A CN 200480016321A CN 1852713 B CN1852713 B CN 1852713B
Authority
CN
China
Prior art keywords
montelukast sodium
acetonitrile
montelukast
dose
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800163215A
Other languages
English (en)
Chinese (zh)
Other versions
CN1852713A (zh
Inventor
周俊宏
M·B·根茨莱尔
J·N·麦克尔斯
吴国杰
C·巴津
S·-D·克拉斯
C·达尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck Sharp and Dohme LLC
Original Assignee
Merck Frosst Canada Ltd
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd, Schering Corp filed Critical Merck Frosst Canada Ltd
Publication of CN1852713A publication Critical patent/CN1852713A/zh
Application granted granted Critical
Publication of CN1852713B publication Critical patent/CN1852713B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN2004800163215A 2003-04-15 2004-04-12 孟鲁司特钠的多晶型 Expired - Fee Related CN1852713B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46294103P 2003-04-15 2003-04-15
US60/462,941 2003-04-15
PCT/US2004/011211 WO2004091618A1 (en) 2003-04-15 2004-04-12 Polymorphic form of montelukast sodium

Publications (2)

Publication Number Publication Date
CN1852713A CN1852713A (zh) 2006-10-25
CN1852713B true CN1852713B (zh) 2010-12-01

Family

ID=33300016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800163215A Expired - Fee Related CN1852713B (zh) 2003-04-15 2004-04-12 孟鲁司特钠的多晶型

Country Status (7)

Country Link
US (1) US7560559B2 (enExample)
EP (1) EP1633357A4 (enExample)
JP (2) JP2006523699A (enExample)
CN (1) CN1852713B (enExample)
AU (1) AU2004229507B2 (enExample)
CA (1) CA2522053C (enExample)
WO (1) WO2004091618A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
EP1709002A2 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
EP1646612B1 (en) 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Processes for preparing montelukast sodium
EP1831171A4 (en) * 2004-11-19 2010-09-15 Matrix Lab Ltd PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
JP2008510840A (ja) 2005-07-05 2008-04-10 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストの精製
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
WO2010064257A1 (en) * 2008-12-01 2010-06-10 Innogent Laboratories Private Limited Novel intermediates for producing [r-(e)]-1-[[[1-[3-[2-(7- chloro -quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy- methylethyl) phenyl]propyl]thio] methyl] cyclopropaneacetic acid, monosodium salt and process thereof
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
WO2011033470A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Crystalline form of montelukast sodium
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
KR100990046B1 (ko) 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN104055741B (zh) * 2013-03-18 2017-02-15 青岛大学 一种孟鲁司特钠片剂及其制备方法
CN104649968B (zh) * 2013-11-25 2017-03-15 天津汉瑞药业有限公司 一种孟鲁司特钠倍半水合物化合物
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN107049940A (zh) * 2017-03-10 2017-08-18 重庆西南医院 一种促进孟鲁司特钠经直肠吸收的促进剂及其使用方法
CN107162969A (zh) * 2017-07-05 2017-09-15 成都亿知科技有限公司 孟鲁司特钠晶体及其制备方法和药物组合物
EP3846792A4 (en) 2018-09-06 2022-10-12 Innopharmascreen Inc. METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US5952347A (en) * 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
EP1119372A1 (en) * 1998-10-09 2001-08-01 Schering Corporation Composition and method for treating allergic diseases
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Also Published As

Publication number Publication date
JP2006523699A (ja) 2006-10-19
US20060194838A1 (en) 2006-08-31
US7560559B2 (en) 2009-07-14
WO2004091618A1 (en) 2004-10-28
AU2004229507A1 (en) 2004-10-28
EP1633357A1 (en) 2006-03-15
JP2010132668A (ja) 2010-06-17
AU2004229507B2 (en) 2008-12-18
CN1852713A (zh) 2006-10-25
EP1633357A4 (en) 2010-02-10
CA2522053A1 (en) 2004-10-28
CA2522053C (en) 2010-06-29

Similar Documents

Publication Publication Date Title
CN1852713B (zh) 孟鲁司特钠的多晶型
DK1981872T3 (en) Succinic salt of biphenyl-2-ylcarbamic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) (5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use in the treatment of pulmonary diseases.
RO112426B1 (ro) Clorhidrat de paraxetina anhidru si solvatat, procedeu de preparare a acestora si metoda de tratare si/sau prevenire a unor tulburari de sanatate
DK1487832T4 (en) Crystalline micronisate of tiotropium bromide
MX2014009544A (es) Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
JP6134377B2 (ja) β２アドレナリン受容体作動薬としての、５−（２−｛［６−（２，２−ジフルオロ−２−フェニルエトキシ）ヘキシル］アミノ｝−１−（Ｒ）−ヒドロキシエチル）−８−ヒドロキシキノリン−２（１Ｈ）−オンヘミナパジシル酸塩の新規の多型結晶形態
KR20080024532A (ko) 신규한 티오트로퓸 염의 제조방법, 신규한 티오트로퓸 염및 이의 약제학적 조성물
TW201012813A (en) Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP7627683B2 (ja) Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態
JP2025514863A (ja) Ｐｄｅ４阻害剤の新規結晶形態
WO2018170724A1 (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
JPS62223183A (ja) 四環式キナゾリノン類
MX2008010205A (es) Sal de acido succinico de 1-[2-(2-cloro-4-[{[r]-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester de acido bifenil-2-ilcarbamico y su uso en el tratamiento de trastornos pulmonar
HK1086557A1 (zh) 结晶单水合物、其制备方法及其在制备药物组合中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101201

Termination date: 20120412